Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of Intratumoral Injection of Carbon Nanoparticle-Loaded Iron Suspension Injection [CNSI-Fe(II)] With Multiple Administrations in Subjects With Advanced Solid Tumors

NCT07433283 is registered in ClinicalTrials.gov with Sichuan Enray Pharmaceutical Sciences Company as lead sponsor.

NCT NCT07433283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07433283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of Intratumoral Injection of Carbon Nanoparticle-Loaded Iron Suspension Injection [CNSI-Fe(II)] With Multiple Administrations in Subjects With Advanced Solid Tumors
Lead sponsor
Sichuan Enray Pharmaceutical Sciences Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 12, 2024
Completion date
December 31, 2026
Enrollment
54 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colorectal cancer, lung cancer, pancreas cancer, thyroid cancer, tumor, solid, vulva cancer